The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Abstract
Objective: To investigate the safety and efficacy of B cell depletion treatment of patients with active primary Sjögren's syndrome of short duration (early primary SS) and patients with primary SS and mucosa‐associated lymphoid tissue (MALT)–type lymphoma (MALT/primary SS). Methods: Fifteen patients with primary SS were included in this phase II trial. Inclusion criteria for the early primary SS group were B cell hyperactivity (IgG >15 gm/liter), presence of autoantibodies (IgM rheumatoid factor, anti‐SSA/SSB), and short disease duration (<4 years). Inclusion criteria for the MALT/primary SS group were primary SS and an associated MALT‐type lymphoma (Ann Arbor stage IE) localized in the parotid gland. Patients were treated with 4 infusions of rituximab (375 mg/m 2) given weekly after pretreatment with prednisone (25 mg) and clemastine. Patients were evaluated, using immunologic, salivary/lacrimal function, and subjective parameters, at baseline and at 5 and 12 weeks after the first infusion. Results: Significant improvement of subjective symptoms and an increase in salivary gland function was observed in patients with residual salivary gland function. Immunologic analysis showed a rapid decrease of peripheral B cells and stable levels of IgG. Human antichimeric antibodies (HACAs) developed in 4 of 15 patients (27%), all with early primary SS. Three of these patients developed a serum sickness–like disorder. Of the 7 patients with MALT/primary SS, complete remission was achieved in 3, and disease was stable in 3 and progressive in 1. Conclusion: Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS. The high incidence of HACAs and associated side effects observed in this study needs further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.554 · Cited by 5,299
Smets, E. M. A., Garssen, B., Bonke, B., & De Haes, J. C. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00125-o · Cited by 3,613
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Diagnostic Tests in the Sicca Syndrome
van Bijsterveld, O. P. (1969) · Archives of Ophthalmology · doi:10.1001/archopht.1969.00990020012003 · Cited by 1,072
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
Conconi, A. (2003) · Blood · doi:10.1182/blood-2002-11-3496 · Cited by 402
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 345
Dörner, T., Egerer, K., Feist, E., & Burmester, G. R. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00013 · Cited by 235
B. Strömbeck, C. E. (2000) · Scandinavian Journal of Rheumatology · doi:10.1080/030097400750001761 · Cited by 190
Fatigue in primary Sjögren's syndrome
Barendregt, P. J., Visser, M. R. M., Smets, E. M. A., Tulen, J. H. M., van den Meiracker, A. H., Boomsma, F., & Markusse, H. M. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.5.291 · Cited by 165
Aalberse, R. C., Dieges, P. H., Knul-Bretlova, V., et al. (1983) · Clinical Reviews in Allergy · doi:10.1007/bf02991163 · Cited by 118
Pijpe, J., van Imhoff, G. W., Vissink, A., van der Wal, J. E., Kluin, P. M., Spijkervet, F. K. L., Kallenberg, C. G. M., & Bootsma, H. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030684 · Cited by 103
Self-citationPrednisone and piroxicam for treatment of primary Sjögren's syndrome.
Fox, P. C., Datiles, M. B., Atkinson, J. C., Macynski, A. A., Scott, J. T., Fletcher, D., Valdez, I. H., Kurrasch, R., Delapenha, R., & Jackson, W. (1993) · PubMed · Cited by 96
Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)
D'Arcy, C. A., & Mannik, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1717::aid-art299>3.0.co;2-c · Cited by 96
Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjögren's syndrome
Kalk, W. W. I., Vissink, A., Stegenga, B. T., Bootsma, H., Amerongen, A. V. N., & Kallenberg, C. G. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.2.137 · Cited by 94
Self-citationPrimary Sjögren's syndrome: salivary gland function and clinical oral findings
Pedersen, A. M. L., Reibel, J., Nordgarden, H., Bergem, H. O., Jensen, J. L., & Nauntofte, B. (1999) · Oral Diseases · doi:10.1111/j.1601-0825.1999.tb00077.x · Cited by 81
Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment
Hellerstedt, B. A., & Ahmed, A. A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg488 · Cited by 69
Oral and ocular manifestations in Sjögren's syndrome.
Kalk, W. W. I., Mansour, K., Vissink, A., Spijkervet, F. K. L., Bootsma, H., Kallenberg, C. G. M., Roodenburg, J. L. N., & Amerongen, A. V. N. (2002) · PubMed · Cited by 30
Self-citationHo (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3
Cited by
Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E., Gottenberg, J.-E., Bootsma, H., Mariette, X., & Vitali, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 965
Self-citationBrito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Self-citationEULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 630
Self-citation
Metadata
- Authors
- Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 52
- Issue
- 9
- Pages
- 2740-2750
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2051649686
- Cited by
- 500
- References
- 29
- FWCI
- 24.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.